ASND vs. MTD: Ascendis Pharma vs. Mettler-Toledo Stock Comparison

November 11, 2026

How do Ascendis Pharma (ASND) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Ascendis Pharma (ASND) and Mettler-Toledo (MTD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ASND is classified in Biotechnology while MTD is classified in Life Sciences Tools & Services.

Company profile comparison for Ascendis Pharma (ASND) and Mettler-Toledo (MTD)
Profile Item	ASND	MTD
Name	Ascendis Pharma A/S	Mettler-Toledo International Inc.
Country/Region	Denmark	Switzerland
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	16.90 billion USD	34.25 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	January 28, 2015	November 14, 1997
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ASND

MTD

GSPC

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Ascendis Pharma (ASND) and Mettler-Toledo (MTD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Ascendis Pharma (ASND) and Mettler-Toledo (MTD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Ascendis Pharma (ASND) and Mettler-Toledo (MTD)
Metric	ASND	MTD
Total Return (1Y)	29.46%	21.58%
Total Return (3Y, Annualized)	40.62%	19.54%
Total Return (5Y, Annualized)	10.03%	2.36%

Risk Profile

Drawdown History

ASND

MTD

GSPC

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Ascendis Pharma (ASND) and Mettler-Toledo (MTD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Ascendis Pharma (ASND) and Mettler-Toledo (MTD)
Metric	ASND	MTD
Volatility (1Y, Annualized)	38.62%	31.70%
Beta (5Y)	0.38	1.15
Max Drawdown (5Y)	-55.93%	-43.47%
Avg. Volume (3M)	698.39K	197.80K

Risk-Adjusted Performance

Risk-Return Positioning

ASND and MTD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Ascendis Pharma (ASND) and Mettler-Toledo (MTD)
Metric	ASND	MTD
Sharpe Ratio (1Y)	0.65	0.55
Sortino Ratio (1Y)	0.99	0.75

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Ascendis Pharma (ASND) earns 118.78% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

118.78%

ASND: 118.78%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
MTD: --

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD): MTD does not report ROE, so it has no value marker; ASND is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Both Ascendis Pharma (ASND) at 70.85% and Mettler-Toledo (MTD) at 22.25% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

70.85%

ASND: 70.85%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.25%

MTD: 22.25%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Ascendis Pharma (ASND) at 64.98% and Mettler-Toledo (MTD) at 28.70% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

64.98%

Max: 83.12%
ASND: 64.98%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.70%

Max: 83.12%
MTD: 28.70%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Ascendis Pharma (ASND) and Mettler-Toledo (MTD)
Metric	ASND	MTD
ROE (TTM)	118.78%	--
ROA (TTM)	9.58%	20.09%
Net Margin (TTM)	70.85%	22.25%
Operating Margin (TTM)	64.98%	28.70%
Gross Margin (TTM)	91.30%	59.16%

Growth

Revenue Growth

Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while Mettler-Toledo (MTD) at 3.98% is closer to the peer norm — faster top-line expansion for ASND.

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Mettler-Toledo (MTD) reports EPS growth of 3.88%, ranked against its industry; Ascendis Pharma (ASND) has no EPS growth figure this period.

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Ascendis Pharma (ASND) and Mettler-Toledo (MTD)
Metric	ASND	MTD
Revenue Growth (YoY)	98.03%	3.98%
Revenue Growth (3Y CAGR)	141.43%	0.90%
EPS Growth (YoY)	--	3.88%
EPS Growth (3Y CAGR)	--	3.06%

Financial Strength

Current Ratio (MRQ)

Ascendis Pharma (ASND) at 2.99 keeps current ratio within its industry’s typical mid-range, while Mettler-Toledo (MTD) at 1.10 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MTD.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.99

Max: 25.13
Q3: 12.13
Median: 5.52
ASND: 2.99
Q1: 2.47
Min: 0.10

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.10

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MTD: 1.10
Min: 0.10

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Ascendis Pharma (ASND) at 0.31 is near its industry mid-range for debt-to-equity ratio, while Mettler-Toledo (MTD) at 26.06 sits above its benchmark range, pointing to a heavier debt load relative to equity.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.31

Max: 1.42
Q3: 0.65
ASND: 0.31
Median: 0.15
Q1: 0.02
Min: 0.00

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.06

MTD: 26.06
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Ascendis Pharma (ASND) and Mettler-Toledo (MTD)
Metric	ASND	MTD
Current Ratio (MRQ)	2.99	1.10
Debt / Equity (MRQ)	0.31	26.06
Net Debt / EBITDA	-1.37	1.58

Dividends

Dividend Yield (TTM)

Neither Ascendis Pharma (ASND) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ASND: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Ascendis Pharma (ASND) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ASND: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Ascendis Pharma (ASND) and Mettler-Toledo (MTD)
Metric	ASND	MTD
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Both Ascendis Pharma (ASND) at 19.68 and Mettler-Toledo (MTD) at 37.38 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.68

Max: 85.34
Q3: 43.46
Median: 26.69
ASND: 19.68
Q1: 13.30
Min: 0.07

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.38

Max: 85.34
Q3: 43.46
MTD: 37.38
Median: 26.69
Q1: 13.30
Min: 0.07

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Ascendis Pharma (ASND) at 16.14 and Mettler-Toledo (MTD) at 8.16 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.14

Max: 58.18
Q3: 25.77
ASND: 16.14
Median: 7.30
Q1: 3.01
Min: 0.01

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 58.18
Q3: 25.77
MTD: 8.16
Median: 7.30
Q1: 3.01
Min: 0.01

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Ascendis Pharma (ASND) at 10.45 sits in the upper P/B ratio quartile, and Mettler-Toledo (MTD) at 442.71 prices even higher, above its industry range.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.45

Max: 13.53
ASND: 10.45
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

442.71

MTD: 442.71
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Ascendis Pharma (ASND) vs. Mettler-Toledo (MTD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Ascendis Pharma (ASND) and Mettler-Toledo (MTD)
Metric	ASND	MTD
P/E Ratio (TTM)	19.68	37.38
P/S Ratio (TTM)	16.14	8.16
P/B Ratio (MRQ)	10.45	442.71
Free Cash Flow Yield (TTM)	0.08%	1.97%